Contact
Header_1077x260px_About_Profil.jpg

Free Online Seminar: Profil - the leading CRO for metabolic research

Profil continues the successful series of scientific online seminars. On October 7th, 2020 at 4 PM CEST we will air our free online seminar. The session is presented by Dr. Lars Bochmann, Director Marketing and Business Development at Profil. 

Read More

Topics: About Profil

Posted by Dr. Lars Bochmann on Sep 21, 2020 4:00:00 PM
dr-lars-bochmann

Profil starts in-house production of tubing sets for ClampArt®, reinforcing the quality of world-class glucose clamp trials

The euglycemic, hyperinsulinemic glucose clamp is the gold standard for the determination of pharmacokinetic and pharmacodynamic (PK/PD) effects of (new) anti-diabetic drugs, in particular insulins. In a typical glucose clamp experiment, a drug-induced decline in blood glucose (BG) concentrations is prevented by infusing glucose with a variable glucose infusion rates (GIR) to keep blood glucose concentrations (BG) as closely as possible to a pre-defined target level. 

Read More

Topics: Clinical Trial Methods, Diabetes Technology

Posted by Dr. Carsten Benesch on Sep 8, 2020 4:02:00 PM
dr-carsten-benesch

The rollercoaster life of inhaled insulin

From Nektar’s award-winning technology to its later commercial failure as Pfizer’s Exubera®. Followed by new hopes for Mannkind’s Afrezza® that suffered more commercial disappointment [1,2,3,4]. The life of pulmonary delivery of insulin (inhaled insulin) has been a thrilling rollercoaster ride. Experts have openly asked whether inhaled insulin has come to the end of its ride or whether there is still a place for inhaled insulin in the future [5]. In this blog article on inhaled insulin, we’ll have a look at what the future may look like and discuss the latest advances with a novel inhaled insulin.

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes

Posted by Dr. Eric Zijlstra on Aug 4, 2020 4:15:00 PM
dr-eric-zijlstra

Heart failure: SGLT2 inhibitors moving beyond diabetes

Sodium/glucose cotransporter 2 (SGLT2) inhibitors have gained momentum in the last few years due to their therapeutic effectivity and the potential to reduce cardiovascular (CV) risks in type 2 diabetes [1, 2, 3].

The mechanisms involved in the improved risk profile observed seem to be a combination of several factors, including blood pressure reduction, increased sodium excretion, weight reduction and improved heart function [4].

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes

Posted by Dr. Jorge Arrubla on Jul 14, 2020 4:15:00 PM
dr-jorge-arrubla

Bringing the real world to clinical research: the use of wearables in pivotal trials

From fitness trackers and health apps to sophisticated sensors and software that support clinical decision, wearables are reshaping the delivery of health care. The use of wearables allows patients to keep track and take control of their own health and can offer primary care professionals with day-to-day insights of patients’ health conditions, allowing early diagnosis and interventions to take place even outside of traditional care facilities. Wearables allow the collection of real-world data in everyday life settings and can be especially useful to enable a precision medicine approach and optimize treatment of chronic diseases [1].

Read More

Topics: Treating Diabetes, Clinical Trial Methods, Diabetes Technology

Posted by Tatiana Dicenzo on Jun 23, 2020 4:00:00 PM
tatiana-dicenzo

Profil World - The clinical diabetes research newsletter - June 2020

Dear all,

Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity.

Read More

Topics: About Profil

Posted by Dr. Lars Bochmann on Jun 2, 2020 3:16:00 PM
dr-lars-bochmann

When Artificial Intelligence and Artificial Pancreas meet

How machine learning methods are changing diabetes research and diabetes care

When voice assistants tell us what the weather will be like, when self-driving cars steer through dense city traffic, or when computers sort our digital photo collections by the faces of our families and friends, whenever computers take over these tasks that would have required human intelligence only a few years back, artificial intelligence (AI) is the underlying technology.

Read More

Topics: Diabetes Technology

Posted by Oliver Klein on May 26, 2020 5:14:00 PM
oliver-klein

Non invasive CGM; hope at the horizon?

Non-invasive Continuous Glucose Monitoring (niCGM) is the holy grail of glucose monitoring. But the quest has been arduous so far; research carried out over the past 35 years has not resulted in in a device with durable availability on the market [1, accessed March 23, 2020].

Two devices have briefly been commercially available. The first, called GlucoWatch Biographer, has been for sale from 2002 to 2007. Poor local tolerability and low accuracy were the limiting factors. The device applied a low voltage current to obtain interstitial fluid transcutaneously. Skin irritation, probably inherent to this technique, together with insufficient accuracy, resulted in withdrawal from the market and dissolvement of the manufacturer [2].

Read More

Topics: Clinical Trials in Diabetes, Diabetes Technology

Posted by Prof. Hans de Vries on May 6, 2020 4:17:00 PM
prof-hans-de-vries

Free Online Seminar on insulin biosimilars

Profil continues the successful series of scientific online seminars. On My 19th, 2020 we will air our free online seminar on insulin biosimilars. The session is presented by Dr. Tim Heise, Lead Scientist and Chairman of the Board of Directors at Profil. 

Read More

Topics: About Profil

Posted by Svenya Meister on Apr 21, 2020 5:12:00 PM
svenya-meister

Think Tank highlights CROs role the adoption of AI-powered health innovation

In recent years there has been rapid growth in the field of medical and health technology. Not only the number of players in this sector has increased over time, but the type of products and services including those that integrate artificial intelligence (AI)-powered components has changed too. These novel health technologies face new challenges in terms of development, validation, implementation, usability and adoption. Innovators can face hurdles not only to obtain regulatory approval but also to achieve sustainable adoption to meet stakeholders’ expectations, as they often require substantial evidence of impact and value before deciding to invest on a novel product. This has implications for the route that companies including Contract Research Organizations (CROs) need to navigate to bring an innovative idea to market.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Mar 31, 2020 5:12:00 PM
prof-dr-freimut-schliess

Subscribe to our monthly blog updates

Find out more: Glucose Clamp Webinar

Subscribe to Email Updates

Our most popular Posts